HGH

Somatropin (recombinant 191aa GH)

HGH (Somatropin (recombinant 191aa GH)) is a gh & growth research compound. The actual growth hormone molecule — direct GH signaling plus liver IGF-1; secretagogues merely coax your own, this replaces it.

How HGH works

The actual growth hormone molecule — direct GH signaling plus liver IGF-1; secretagogues merely coax your own, this replaces it.

Proposed benefits

Researched for lean-mass support, recovery, sleep depth, connective-tissue repair and improved body composition via the GH/IGF-1 axis.

Can you actually get HGH?

The evidence for HGH

Graded by what exists behind each claim.

✅ Clinically validated

• A fully approved human drug with decades of trial data, licensed for pediatric growth failure, adult GH deficiency, Turner syndrome, HIV wasting and short bowel syndrome. The pharmacology is not in question.
• The famous 1990 Rudman study in older men — increased lean mass, decreased fat — is the origin of anti-ageing use, and it is routinely quoted without its follow-up: subsequent work found the body-composition changes came with joint pain, edema, carpal tunnel and impaired glucose tolerance, and did not translate into functional improvement.

📊 Correlative data

• Extensive off-label use. What the record adds to the trials is that the side-effect profile is strongly dose-dependent — the problems cluster at supraphysiological doses, and much of modern practice uses far less than the 1990s protocols did.

🧪 Theoretical / extrapolated

• Exogenous growth hormone, acting directly rather than through the pituitary. That is the key mechanistic distinction from every secretagogue on this site: it bypasses feedback entirely, so it works regardless of pituitary function and it suppresses your own production while you use it.
• Continuous non-pulsatile signaling predicts the insulin resistance, and IGF-1-driven proliferation predicts the long-standing and unresolved question about cancer risk.

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What HGH actually does

Somatropin is 191 amino acids, about 22,000 daltons, and its amino acid sequence is identical to human growth hormone of pituitary origin Norditropin label. That word — identical — is what separates it from everything else in the growth-hormone aisle. Secretagogues persuade a pituitary to release its own; this is the molecule itself.

How one hormone activates a receptor that is already a dimer. The growth hormone receptor sits in the membrane as a pre-formed pair. A single hormone molecule carries two non-identical binding surfaces — a high-affinity face and a lower-affinity one — and engages one receptor with each, rotating the two intracellular tails into alignment. That rotation brings the associated JAK2 kinases into contact, they trans-phosphorylate, STAT5b is recruited and phosphorylated, and it moves to the nucleus to drive transcription of IGF-1 in the hepatocyte. One ligand, two receptor molecules, one rotation.

The consequence of that stoichiometry is a mechanism almost nobody in this market has met, and it argues against large doses. If the hormone's job is to bridge two receptors, then at sufficiently high concentration every receptor gets its own hormone molecule on its high-affinity face and there is nothing left to bridge. The dose-response for receptor dimerization is therefore bell-shaped: signaling rises with concentration, peaks, and then falls as excess ligand blocks its own bridging. This is not speculation about a mechanism — it is the design principle behind the marketed GH receptor antagonist, which is a modified GH molecule with site 2 deliberately broken. Extrapolated, clearly labeled as such: it predicts that a single large injection is less efficient per unit than the same total split across the day, and no human dose-response study has ever tested that on this molecule.

Two arms, opposite metabolic signs. The direct GH arm is lipolytic and insulin-antagonistic; the indirect arm is IGF-1, which is anabolic and insulin-like. That is why the label's own warning is that somatropin may decrease insulin sensitivity, particularly at higher doses Norditropin label, at the same time as the marketing claims are about body composition. Both are true and they are the same pharmacology.

What GH does in muscle, measured rather than asserted. Work in this field found that in muscle GH stimulates the anaerobic and suppresses the aerobic energy system Ho 2019. That single sentence explains the entire pattern of results in the athletic literature better than any claim about tissue growth does.

Cell, rodent, human — and where it stops

Step one, the replacement evidence, which is not in dispute. Somatropin is an approved drug with an adult growth-hormone-deficiency indication and a defined starting dose: approximately 0.2 mg/day, range 0.15 to 0.3 mg/day, titrated in 0.1–0.2 mg increments every one to two months, or weight-based from 0.004 mg/kg to a maximum 0.016 mg/kg daily, with the weight-based approach explicitly not recommended for obese patients Norditropin label.

Now convert, because the conversion is the finding. One milligram of somatropin is about 3 international units. The adult replacement starting dose of 0.2 mg/day is therefore roughly 0.6 IU/day, and the label's titrated adult range tops out around 0.9 IU/day in the non-weight-based scheme. The dose range printed on this compound's card is 1–4 IU/day. The lowest number in common non-medical use is above the top of the approved adult replacement range, and the highest is roughly six times it. Every safety percentage on the label was generated at replacement doses.

Step two, the athletic evidence, from the group that ran the trials. In recreational athletes GH improves anaerobic capacity but has not been proven to significantly enhance muscle strength, power, or maximum oxygen consumption, and is likely to selectively benefit sprint events rather than performance depending on strength or endurance Ho 2019. Read the shape of that result: one energy system moved, the two headline qualities people buy it for did not.

Step three, the proteomics, which is the most interesting human dataset on this molecule and is almost unknown. Thirty-five recreational athletes received one of three recombinant hGH doses or placebo, with samples at 22 time points over 13 weeks. Across 749 serum samples, 66 proteins associated significantly with administration and dose — IGF-1 as expected, but also previously unrecognized ones including WFIKKN1 and CCL2, with network analysis pointing at immune-system and glucose-metabolism pathways Esefeld 2021. The authors' own conclusion is that hGH affects biological processes more substantially than previously acknowledged.

Why WFIKKN1 deserves a sentence of its own. It is a circulating protein that binds and inhibits members of the TGF-beta/myostatin family. If growth hormone moves it dose-dependently in humans Esefeld 2021, that is a plausible route from GH to muscle that does not run through IGF-1 at all — and it sits directly alongside the activin-receptor pharmacology of bimagrumab elsewhere in this Vault. Nobody has tested whether the two interact.

The obstacles. (1) The efficacy evidence is in deficiency; the use is in sufficiency. (2) No published dose-response study exists for body composition at the doses actually used. (3) The proteomic work identified biomarkers, not outcomes. (4) The wider performance-enhancing-peptide literature that surrounds this axis is reviewed as an emerging landscape rather than a settled one Dominikowski 2026.

HGH pharmacokinetics — how much of it actually gets in

The card says ~3–5 hours subcutaneous. The label for one marketed somatropin says something different and more useful, and the difference is the most instructive thing on this page.

The two half-lives. After intravenous administration the terminal half-life is approximately 21.1 (5.1) minutes. After subcutaneous injection the apparent terminal half-life is approximately 7 to 10 hours in growth-hormone-deficient patients. Clearance is approximately 2.3 (1.8) mL/min/kg, and after a 4 mg subcutaneous dose the mean peak was 34.9 ng/mL at approximately 3.0 hours Norditropin label. Absolute subcutaneous bioavailability is stated as not known — on the label, in those words.

A twenty-fold gap between the intravenous and subcutaneous figures is not a contradiction. It is flip-flop kinetics. When absorption from the injection depot is slower than elimination from plasma, the number you measure as a terminal half-life is the absorption rate wearing elimination's clothes. The molecule is still cleared in about twenty minutes; it simply cannot leave the subcutaneous tissue that fast. Two things follow. First, the subcutaneous half-life is a property of the injection site and the formulation, which is why different somatropin products quote different numbers and why a single figure on a card cannot be right for all of them. Second, intramuscular or intravenous administration does not extend anything — it shortens everything, converting a several-hour exposure into a twenty-minute one.

The arithmetic that matters. The label's 34.9 ng/mL peak came from 4 mg, roughly 12 IU. Scaling linearly, a 2 IU dose lands near 6 ng/mL — squarely inside the range a healthy pituitary reaches at the top of its own nocturnal pulses. The difference is not the height of the peak. It is that a natural pulse collapses within minutes and an injected one is held for hours by the depot. Injecting growth hormone does not primarily raise the peak; it abolishes the trough, and receptor systems built around pulses generally respond to a lost trough by downregulating.

Oral is not a route for this molecule and never will be. A 22 kDa protein is dismantled by pepsin and pancreatic proteases and is far above the size limit for passive intestinal absorption; anything surviving would meet first-pass hepatic extraction. Every approved presentation is a subcutaneous injection Norditropin label.

What would have to be true, and how you would know it was not

Three predictions with markers, directions and windows. The third is the one the mechanism forces and the marketing omits.

1. IGF-1 must rise, and it is the only honest titration target. The hepatic IGF-1 response is the direct readout of receptor engagement, and it was among the 66 proteins that tracked dose in a controlled human study Esefeld 2021. Prediction: IGF-1 drawn at baseline and again at 4 to 6 weeks on a stable dose rises measurably. If it does not, one of two things is true — the material is not what it claims to be, or the dose is not reaching the liver — and no amount of subjective response should override a flat IGF-1. This is the falsifier that costs one tube of blood.

2. Insulin sensitivity should worsen before anything visible improves. The label states plainly that somatropin may decrease insulin sensitivity, particularly at higher doses Norditropin label, and the human proteomic network pointed at glucose metabolism Esefeld 2021. Prediction: fasting insulin rises and HbA1c drifts upward within 8 to 12 weeks at doses above replacement. Fasting glucose alone will miss this for months, because insulin rises first to hold glucose steady — measuring glucose without insulin is the standard way people conclude nothing is happening.

3. Against the product: the strength prediction is negative. The controlled literature says GH improves anaerobic capacity and has not been shown to increase muscle strength, power or VO2max Ho 2019. So the prediction is testable and unflattering: over a 12-week block with training held constant, a person on GH should show measurable improvement in a short all-out effort and no advantage in maximal strength over an appropriately matched comparison. If someone's one-rep maximum climbs, the training block or the food is the more probable explanation, and attributing it to GH is exactly the inference the trials were designed to test and did not support.

What nobody has tested yet

Four experiments, all of which use instruments that already exist.

Whether divided dosing beats a single injection. The bell-shaped dimerization argument above predicts it should, at least at higher totals, and the depot's flip-flop kinetics mean the comparison would be easy to run: same daily total, one injection against two, IGF-1 and fasting insulin as endpoints, four weeks per arm. Nobody has published it at any dose.

What WFIKKN1 does downstream in a human on growth hormone. It moved with dose in the only proteomic study of its kind Esefeld 2021 and it is a myostatin-family inhibitor. Whether that translates into a measurable change in muscle protein turnover has never been asked, and it is the most concrete new hypothesis about GH and muscle to come out of human data in years.

Whether any of the 66 proteins predicts a responder. The study identified proteins that respond to the drug Esefeld 2021. The far more useful question — which baseline protein predicts who will respond, and to what — requires only a reanalysis of data that already exists.

What happens to the trough. Every argument on this page about abolishing the physiological trough is inference from published kinetics Norditropin label. Actually measuring 24-hour GH profiles in people on exogenous somatropin at non-replacement doses, and looking at whether endogenous pulsatility returns between injections, would settle it. The assay is standard and the study has not been done in this population.

HGH — its own safety story, not its class's

The label's warnings are the risk profile, and three of the four are dose-dependent in a population that dose-escalates.

Insulin sensitivity. Somatropin may decrease it, particularly at higher doses Norditropin label. This is the warning most relevant to non-medical use, because non-medical use is defined by being above the doses the warning was written for. It is also silent: nothing about it is felt, and it is detectable on an ordinary panel long before it produces a symptom.

Fluid retention, and the specific form it takes. The label describes edema, arthralgia, myalgia and nerve compression syndromes including carpal tunnel syndrome and paraesthesias as usually transient and dose dependent Norditropin label. The mechanism is sodium and water retention in a closed compartment, which is why the wrist is where it shows up first — the carpal tunnel has no room to expand. Transient means it resolves on dose reduction, not that it can be ignored.

Intracranial hypertension, and its timing. Symptoms usually occurred within the first eight weeks after starting Norditropin label. That is a specific, actionable window: a new persistent headache with visual change in the first two months of use is a reason to stop and be examined, not a reason to push through.

The neoplasm warning, stated precisely rather than dramatically. The label's warning concerns an increased risk of second neoplasms in pediatric cancer survivors previously treated with cranial radiation who develop GH deficiency Norditropin label. It is not a general statement that growth hormone causes cancer, and reporting it as one would be dishonest in the other direction. What is genuinely unresolved is what decades of supraphysiological IGF-1 does in an adult with no deficiency, and the answer is that no controlled dataset exists.

The supply problem specific to this molecule. Somatropin is a 22 kDa protein that must be correctly folded to work; a misfolded or aggregated preparation is inactive and immunogenic rather than merely weak. IGF-1 at four weeks is the only practical assay a buyer has Esefeld 2021, and a flat IGF-1 is the honest answer to what is in the vial.

Sources read for this page

• U.S. Food and Drug Administration. NORDITROPIN (somatropin) injection, for subcutaneous use — full prescribing information. DailyMed, U.S. National Library of Medicine
• Ho KKY, Nelson AE. The promise of growth hormone in sport: doped or duped. Archives of Endocrinology and Metabolism 2019 · PMID 31939482
• Esefeld M, et al. The Proteomic Signature of Recombinant Growth Hormone in Recreational Athletes. Journal of the Endocrine Society 2021 · PMID 34765854
• Dominikowski A, Rekos Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchala M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.. Front Endocrinol (Lausanne) 2026 · PMID 42395176

HGH — safety, predicted from mechanism

HGH — interference & stacking

Bloodwork to run alongside HGH

Baseline first, then again at 8–12 weeks.

The “Running GH Peptides or MK-677” panel covers these in one order — 9 markers, $132.30 with the discount applied.

Check results you already have → · All 103 markers A–Z

HGH — frequently asked questions

What HGH is used for

HGH appears under 1 goal in the goal router.

Related GH & Growth compounds

← Explore the full Protocol Vault

↑ Back to on this page